A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
Selected Advanced Solid Tumors
BIOLOGICAL: MEDI5752|DRUG: Pemetrexed|DRUG: Carboplatin|BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel or Nab-Paclitaxel
The number of subjects experiencing treatment related adverse events (AEs) (Dose-escalation phase), The primary endpoint is as assessed by the number of subjects experiencing adverse events (AEs) graded per NCI CTCAE v4.03, From the time of informed consent through 114 days following termination of treatment with investigational product|Preliminary anti-tumor activitiy of MEDI5752 (versus pembrolizumab, where applicable) using Objective Response based on RECIST v1.1 (Dose-expansion phase), The primary endpoint of antitumor activity include Objective Response and will be based on all post baseline disease assessments that occur prior to initiation of subsequent anticancer therapy., From the first dose of study drug through the date of first documented progression, end of study, date of death, or two years after the last patient starts treatment, whichever should occur first|The number of subjects experiencing dose-limiting toxicities (DLTs) (Dose-escalation phase), The primary endpoint is as assessed by the number of subjects experiencing dose limiting toxicities (DLTs) as defined by the protocol., Up to 21 days following the first dose|The number of subjects experiencing abnormal laboratory evaluations (Dose-escalation phase), The primary endpoint is as assessed as the number of subjects experiencing changes in laboratory parameters from baseline., From the time of informed consent through 114 days following termination of treatment with investigational product|The number of subjects experiencing changes from baseline in vital signs reported as adverse events (Dose-escalation phase), The primary endpoint is as assessed by the number of subjects experiencing clinically significant changes in vital signs from baseline., From the time of informed consent through 114 days following termination of treatment with investigational product|The number of subjects experiencing abnormal electrocardiograms (ECG) reported as Adverse Events (Dose-escalation phase), The primary endpoint is as assessed by the the number of subjects experiencing clinically significant changes in ECG parameters from baseline., From the time of informed consent through 114 days following termination of treatment with investigational product|The number of subjects experiencing treatment related serious adverse events (SAEs) (Dose-escalation phase), The primary endpoint is as assessed by the number of subjects with serious adverse events (SAEs) graded per NCI CTCAE v4.03., From the time of informed consent through 114 days following termination of treatment with investigational product
Pharmacokinetics of MEDI5752: Cmax, The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include maximum observed concentration (Cmax), To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment|Pharmacokinetics of MEDI5752: AUC, The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include area under the concentration-time curve (AUC), To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment|Pharmacokinetics of MEDI5752: Clearance, The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include clearance (CL), To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment|Pharmacokinetics of MEDI5752: t 1/2, The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include terminal phase half life (t 1/2), To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment.|Ability of MEDI5752 to generate immune response in subjects with advanced solid tumors, The endpoints for the immunogenicity of MEDI5752 include the number of subjects who develop detectable anti-drug antibodies (ADAs), To be assessed at Day 1, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment.|PD-L1 Expression in subjects with advanced solid tumors, The endpoint for the PD-L1 expression will be determined by Immunohistochemistry characterization., To be assessed at baseline|Preliminary Antitumor Activity: Duration of Response, The endpoints for assessment of antitumor activity include duration of response (DoR) and is defined as the duration from the documentation of OR to the first documentation of disease progression or death due to any cause., From the date of response through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first|Preliminary Antitumor Activity: Disease Control, The endpoints for assessment of antitumor activity include disease control (DC) and is defined as CR, PR, or SD according to RECIST v1.1., From the first dose of study drug through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first|Preliminary Antitumor Activity: Progression Free Survival, The endpoints for assessment of antitumor activity include progression free survival (PFS) and is defined as the duration measured from the start of treatment with investigational product to the first documentation of disease progression or death due to any cause., From the first dose of study drug through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first|Preliminary Antitumor Activity: Overall Survival, The endpoints for assessment of antitumor activity include overall survival (OS) and is defined as the duration measured from the start of treatment with investigational product until death due to any cause., From the first dose of study drug through the end of study, or date of death, or two years after last subject starts treatment whichever should occur first|The number of subjects experiencing treatment related adverse events (AEs) (Dose-expansion phase), The secondary endpoint is as assessed by the number of subjects experiencing adverse events (AEs) graded per NCI CTCAE v4.03, From the time of informed consent through 114 days following termination of treatment with investigational product|The number of subjects experiencing abnormal laboratory evaluations (Dose-expansion phase), The secondary endpoint is as assessed by the number of subjects experiencing changes in laboratory parameters from baseline., From the time of informed consent through 114 days following termination of treatment with investigational product|The number of subjects experiencing Changes from baseline in vital signs reported as adverse events (Dose-expansion phase), The secondary endpoint is as assessed by the number of subjects experiencing clinically significant changes in vital signs from baseline., From the time of informed consent through 114 days following termination of treatment with investigational product|The number of subjects experiencing abnormal ECGs reported as adverse events (Dose-expansion phase), The secondary endpoint is as assessed by the number of subjects experiencing clinically significant changes in ECG parameters from baseline., From the time of informed consent through 14 days following termination of treatment with investigational product|The number of subjects experiencing treatment related serious adverse events (SAEs) (Dose-expansion phase), The secondary endpoint is as assessed by the number of subjects with serious adverse events (SAEs) graded per NCI CTCAE v4.03, From the time of informed consent through 114 days following termination of treatment with investigational product
This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics and Immunogenicity of MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.